Physician profile
Prashant Kumar Joshi
NPI 1316946890
$5,173.20
in general payments reported to CMS, 2019-2025
20 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,593 · 2020: $230 · 2021: $482 · 2022: $282 · 2023: $27.61 · 2024: $115 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,200 · Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,200.00 |
| Food and Beverage | $386.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,226.59 | 2019 | |
| Galvanize Therapeutics, INC | $1,379.92 | 2025 | Aliya System |
| Lilly USA, LLC | $313.56 | 2020-2023 | Verzenio, Jaypirca |
| Merck Sharp & Dohme LLC | $203.20 | 2019-2025 | Keytruda |
| Janssen Biotech, INC. | $177.60 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $169.57 | 2019-2022 | |
| Genzyme Corporation | $162.37 | 2019-2021 | |
| Tempus Ai, INC | $93.91 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $65.32 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $64.99 | 2019 | |
| Allergan, INC. | $58.88 | 2020 | |
| Celgene Corporation | $40.54 | 2021-2025 | Reblozyl |
| Puma Biotechnology, INC. | $37.89 | 2020 | |
| Janssen Pharmaceuticals, INC | $37.50 | 2021 | |
| Seagen INC. | $32.35 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $24.96 | 2019 | |
| Pfizer INC. | $23.36 | 2019 | |
| Global Blood Therapeutics, INC. | $21.03 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $20.35 | 2020 | |
| Glaxosmithkline, LLC. | $19.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.